Phamacokinetics of rivaroxaban in adolescents

Hamostaseologie

Volumn 34, Issue 1, 2014, Pages 85-87

  Beyer Westendorf, J ^a   Gehrisch, S ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Adolescents; Pharmacokinetics; Rivaroxaban

Indexed keywords

CHLORMADINONE ACETATE; ETHINYLESTRADIOL; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BLOOD CLOTTING TEST; CASE REPORT; COMPRESSION STOCKING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD; METABOLIC CLEARANCE RATE; VENOUS THROMBOSIS;

ADOLESCENT; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; METABOLIC CLEARANCE RATE; MORPHOLINES; THIOPHENES; VENOUS THROMBOSIS;

EID: 84896278844     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-06-0033     Document Type: Article

References (11)

1. Mueck W, Borris LC, Dahl OE et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
2. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012; 26: 27-32.
3. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013; 11: 10.
4. Buller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
5. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
6. Streif W, Ageno W. Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children. Wien Med Wochenschr 2011; 161: 73-79.
7. Mani H, Rohde G, Stratmann G et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108: 191-198.
8. Mahlmann A, Gehrisch S, Beyer-Westendorf J. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 2013; (Vol. Seiten ggfs. DOI; Autor bitte ergänzen).
9. Zhao X, Sun P, Zhou Y et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol 2009; 68: 77-88.
10. Mueck W, Lensing AW, Agnelli G et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
11. Kubitza D, Becka M, Voith B et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.